These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16789739)

  • 21. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
    Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
    Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
    Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
    Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
    Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
    Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
    Dean JL; Thangavel C; McClendon AK; Reed CA; Knudsen ES
    Oncogene; 2010 Jul; 29(28):4018-32. PubMed ID: 20473330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
    Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
    Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
    Casimiro MC; Velasco-Velázquez M; Aguirre-Alvarado C; Pestell RG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):295-304. PubMed ID: 24387133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.
    Brotherton DH; Dhanaraj V; Wick S; Brizuela L; Domaille PJ; Volyanik E; Xu X; Parisini E; Smith BO; Archer SJ; Serrano M; Brenner SL; Blundell TL; Laue ED
    Nature; 1998 Sep; 395(6699):244-50. PubMed ID: 9751051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.
    Toogood PL; Harvey PJ; Repine JT; Sheehan DJ; VanderWel SN; Zhou H; Keller PR; McNamara DJ; Sherry D; Zhu T; Brodfuehrer J; Choi C; Barvian MR; Fry DW
    J Med Chem; 2005 Apr; 48(7):2388-406. PubMed ID: 15801831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
    Caballero J; Fernández M; González-Nilo FD
    Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
    Laman H; Funes JM; Ye H; Henderson S; Galinanes-Garcia L; Hara E; Knowles P; McDonald N; Boshoff C
    EMBO J; 2005 Sep; 24(17):3104-16. PubMed ID: 16096642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoids induce G1 as well as S-phase lengthening in normal human stimulated lymphocytes: differential effects on cell cycle regulatory proteins.
    Baghdassarian N; Catallo R; Mahly MA; Ffrench P; Chizat F; Bryon PA; Ffrench M
    Exp Cell Res; 1998 May; 240(2):263-73. PubMed ID: 9596999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective degradation of CDK6 by a palbociclib based PROTAC.
    Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and SARs of 5-Chloro-
    Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
    J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.
    Hernandez Maganhi S; Jensen P; Caracelli I; Zukerman Schpector J; Fröhling S; Friedman R
    Protein Sci; 2017 Apr; 26(4):870-879. PubMed ID: 28168755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
    Su S; Yang Z; Gao H; Yang H; Zhu S; An Z; Wang J; Li Q; Chandarlapaty S; Deng H; Wu W; Rao Y
    J Med Chem; 2019 Aug; 62(16):7575-7582. PubMed ID: 31330105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.